Pregnancy following regression of uterine submucosal leiomyoma with GnRH therapy; a case report.

Détails

ID Serval
serval:BIB_C1C63F853761
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Pregnancy following regression of uterine submucosal leiomyoma with GnRH therapy; a case report.
Périodique
European Journal of Obstetrics, Gynecology, and Reproductive Biology
Auteur(s)
Volpe A., Adamo R., Coukos G., Silferi M., Artini P.G., Genazzani A.R.
ISSN
0301-2115 (Print)
ISSN-L
0301-2115
Statut éditorial
Publié
Date de publication
1991
Volume
39
Numéro
3
Pages
223-225
Langue
anglais
Notes
Publication types: Case Reports ; Journal ArticlePublication Status: ppublish
Résumé
A patient with a history of two spontaneous abortions, at the 16th and 20th week, respectively, and one intra-uterine fetal death at the 26th week of gestation was investigated. The sole abnormal condition that could be evidenced was a submucosal leiomyoma of 56 mm in diameter in the uterine fundus. Administration of gonadotropin/releasing hormone analog (GnRHa) for 10 months resulted in complete disappearance of myoma. Direct intraperitoneal insemination following induction of ovulation resulted in pregnancy. In a patient harboring uterine leiomyomas, adversely affecting conception and pregnancy outcome, GnRHa treatment may be an initial approach allowing to avoid pelvic surgery. As the beneficial effect of GnRHa might be temporary, assisted reproduction procedures might anticipate conception.
Mots-clé
Abortion, Spontaneous/etiology, Adult, Buserelin/therapeutic use, Female, Humans, Infertility, Female/etiology, Infertility, Female/therapy, Insemination, Artificial, Homologous, Leiomyoma/complications, Leiomyoma/drug therapy, Pregnancy, Pregnancy Complications, Neoplastic, Uterine Neoplasms/complications, Uterine Neoplasms/drug therapy
Pubmed
Web of science
Création de la notice
14/10/2014 12:43
Dernière modification de la notice
03/03/2018 21:08
Données d'usage